The North American MEA Workshop is focused on new in vitro microelectrode array approaches for assessing cardiac and neuronal activity. MEA technology is currently being evaluated as part the CiPA initiative to guide future regulatory cardiac safety testing. It is also a powerful tool for in vitro assessment of electrophysiologically-neurotoxic response.
At the workshop, leaders in the field will present their experiences on how MEA is being utilized within large Pharma companies and other organizations.
This event is free of charge; hot buffet lunch and parking are included.
May 15, 2015 10:00 am - 2:30 pm (Sign-in/Registration at 9:30)
Philadelphia Marriott West, West Conshohocken, PA
|Stacie Chvatal, PhD
|The Maestro Multiwell MEA Platform: A Simple Approach to Modeling Complex Human Systems In Vitro|
|Khuram Chaudhary, PhD
|In Vitro Assessment of Drug-Induced Seizure Liability Using a Multi-Electrode Array Based Rat Cortical Neuronal Assay|
|Hong Shi, MD
|In Vitro Proarrhythmia Assays on Human iPSC Cardiomyocytes and Multielectrode Array Systems|
|Mark Estacion, PhD
|Use of MEA Technology to Facilitate Characterization of Pain-Associated hNav1.7 Channel Mutations|
|Christopher Strock, PhD
|MEA Based Assays to Predict Toxicity in Neuro and Cardiac Cellular Models: Using Electrophysiology to Predict Subcytotoxic Liabilitites|
Stacie Chvatal is a Field Applications Scientist at Axion Biosystems. Dr. Chvatal earned a Bachelor of Science in Engineering from Mercer University and a Ph.D. in biomedical engineering from the Georgia Institute of Technology and Emory University. From 2011 to 2013, she worked as a postdoc at GA Tech researching neural control of movement in humans and animals, in both healthy and impaired nervous systems. Since 2013, she has worked at Axion BioSystems, where she helps customers achieve their scientific objectives using Axion’s multiwell MEA system to model and study electrophysiological activity in cardiac and neural networks.
Khuram Chaudhary, PhD is the U.S. head of ion channel pharmacology in Safety Assessment at GSK. He graduated from Temple University School of Medicine, where he received a doctorate in Human Physiology and studied abnormalities in calcium homeostasis and excitation contraction coupling in congestive heart failure. His post-doctoral training was at Pharmacia/Pfizer in Safety Pharmacology- designing novel approaches to study acquired long-QT syndrome. He joined GSK in 2006 and has been contributing to Safety Pharmacology for more than 13 years. His lab is currently investigating off-target CNS and cardiovascular ion channel liabilities. He also serves as a representative for GSK on several ILSI/HESI committees including the CiPA initiative.
Hong received her MD degree from Shanghai Jiao Tong University School of Medicine in China. She practiced as a resident and attending physician in Department of Ob&Gyn for 6 years in Ruijin Hospital affiliated to Jiao Tong University School of Medicine. She began her cardiac ion channel research as a postdoctoral fellow in Montreal Heart Institute. Within 3 years, she identified novel subtypes of membrane receptors in the heart and a novel potassium channel likely representing the first Gq protein gated potassium channel. She received the MRC Fellowship from the Medical Research Council of Canada. After her postdoctoral training, she worked with Pfizer on in-vitro cardiovascular safety pharmacology. In 2001, she joined Bristol-Myers Squibb working on cardiac ion channel discovery and safety pharmacology. In 2006, Hong introduced Multi-electrode Array technology to cardiovascular safety study in BMS. From 2009, she led the novel cardiac safety assay combining human induced pluripotent stem cells and multi-electrode array technologies to improve the translational power of pre-clinical assays to clinical outcomes. Hong has authored and co-authored 22 research publications on high impact peer-reviewed journals and more than 50 abstracts. Hong has been invited to present at various international conferences, user meetings and workshops. She serves in Safety Pharmacology Society program committee, abstract committee, and student and travel award committee. She is a member of HESI Cardiac Stem Cell Working Group and HESI/CiPA Myocyte MEA Subteam.
Bio coming soon.
Chris Strock received his BS in Chemistry from Gannon University in Erie, PA. He worked as an organic chemist for DuPont Ag for a few years before getting his PhD in Biochemistry and Molecular Biology from the University of Maryland, Baltimore where he determined the calcium binding sites on the SR Calcium ATPase. He was a postdoctoral Fellow and Research Associate in the Oncology Department at Johns Hopkins University School of Medicine under Barry Nelkin, PhD where he identified CDK5, a protein important in migration of cells in neural development, as an essential molecule for metastasis in numerous cancer models. He then joined Cellumen where he developed his expertise in High Content Screening technology. While there he specialized in assay development and was responsible for the design and development of High Content HTS Protein: Protein Interaction biosensor assays. He also worked in the HCS toxicology group in developing and optimizing assays for the in vitro toxicology assay, CellCiphr. After Cyprotex acquired Cellumen, Chris joined Cyprotex US in Watertown, MA where he has brought his expertise in the area of HCS assay development.